<DOC>
	<DOCNO>NCT01747239</DOCNO>
	<brief_summary>Ovarian cancer patient consider platinum refractory disease worsen primary platinum treatment effect treatment . This constitute major therapeutic problem new treatment approach highly need . Cabazitaxel ( Jevtana® ) new taxane effect breast prostatic cancer . In tumor effect patient refractory taxotere . Consequently , could anticipate cabazitaxel may effect platinum refractory ovarian cancer .</brief_summary>
	<brief_title>Cabazitaxel Platinum Refractory Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>Histologically confirm epithelial , primary fallopian primary peritoneal cancer . Stages IIV . Patients refractory disease define progression change primary treatment , evaluate 3 and/or 6 cycle platinum/paclitaxel . Prior inclusion , patient must receive platinum paclitaxel combination treatment . Measurable disease Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 evaluable Gynecologic Cancer Interest Group ( GCIG ) cancer antigen 125 ( CA125 ) criterion . Age ≥ 18 year . Performance stage 02 . Adequate bone marrow function , liver function , renal function , coagulation parameter ( within 7 day prior inclusion ) : 1 . Neutrophils ( ANC ) ≥ 1.5 x 10^9/l 2 . Platelet count ≥ 100 x 10^9/l 3 . Serum bilirubin ≤ 1.0 x upper limit normal ( ULN ) 4 . Serum transaminase ≤ 2.5 x ULN 5 . Serum creatinine ≤ 1.5 ULN . If creatinine 1.0 1.5 x ULN , creatinine clearance calculate accord Chronic Kidney Disease Epidemiology Collaboration formula ( CKDEPI ) patient creatinine clearance &lt; 60 mL/min exclude Written informed consent . History severe hypersensitivity reaction ( ≥grade 3 ) taxol . History severe hypersensitivity reaction ( ≥grade 3 ) polysorbate 80 contain drug . Concurrent plan treatment strong inhibitor strong inducer cytochrome P4503A4/5 ( one week washout period necessary patient already treatment ) . Neuropathy grade ≥ 2 . Pregnant breastfeeding patient . For fertile woman negative pregnancy test screen mandatory . Fertile patient willing use effective method contraception treatment 6 month end treatment . Other malignant disease within 5 year prior inclusion study , except basal cell squamous cell carcinoma skin cervical carcinomainsitu . Other experimental therapy participation another clinical trial within 28 day prior treatment initiation . History chronic medical psychiatric condition laboratory abnormality medically control opinion investigator may increase risk associated study drug administration . ( e.g . diabetes , cardiac disease , hypertension , renal , thyroid liver disease ) . Vaccination yellow fever vaccine live attenuated vaccine treatment . Treatment disulfiram ( antabuse )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Ovarian cancer</keyword>
	<keyword>Platinum refractory</keyword>
</DOC>